DNA-nanoparticle motors are exactly as they sound: tiny artificial motors that use the structures of DNA and RNA to propel ...

Biogen’s applications for the higher dose regimen of SMA drug Spinraza are now under review in the US and Europe.

The Massachusetts based biotech will now press ahead with human trials for its antisense oligonucleotide (ASO) therapy, ...

New guidelines will help doctors identify patients with a common memory-loss syndrome that is often misdiagnosed as Alzheimer's disease in older adults. The diagnostic criteria for limbic-predominant ...

Funding for motor neurone disease (MND) research has received a boost through a unique fundraising initiative involving vintage trucks. Dr. Lotta Oikari, a senior research officer at QIMR Berghofer ...

An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines Agency (EMA) considerate it as an alternative than the current lower ...

Investing.com -- Shares of Ionis Pharmaceuticals (NASDAQ: IONS) climbed 7% today after the company announced that regulatory agencies in the United States and Europe have accepted applications for a ...

We are pleased to announce that our applications for the higher dose regimen of nusinersen are now under review in the US and Europe,” said Stephanie Fradette, Pharm.D., Head of the Neuromuscular ...

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

This slopestyle MTB course is huge! I'm at Crankworx Rotorua 2019 in New Zealand - where I'll be competing in the mountain bike slopestyle event. Stay tuned in to see all the MTB riding footage from ...

Is the classic automobile history and the future of mobility purely electric and autonomous? Not necessarily, says Stepan ...

Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose regimen of nusinersen to advance the treatment of SMA CAMBRIDGE, Mass., Jan. 2 ...